About: Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 04 March 2014

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2014 (ast) наукова стаття, опублікована в березні 2014 (uk) مقالة علمية نشرت في 04 مارس 2014 (ar) scientific article published on 04 March 2014 (en)
publication date	wds:Q37711688-233223EC-524B-4AC6-B6DF-2068E697C635
publication date	2014-03-04 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37711688-8257591A-A9B9-4FAB-A844-AFCF7C5E5E3C
language of work or name	English
exact match	wds:Q37711688-B3955AAB-D08E-4C28-B257-33ED203492F5
exact match	https://scigraph.springernature.com/pub.10.1038/bjc.2014.72
cites work	wds:Q37711688-0B1EFF3A-CC37-4708-A02E-CEE62F4AE356 wds:Q37711688-0ED0580A-2C4D-434B-B1B4-EA6E1F65D84C wds:Q37711688-16F3B399-E473-4D86-9153-1B3DC761746E wds:Q37711688-2550BF93-C818-4A80-950D-347780A5C445 wds:Q37711688-445C0177-1521-4FF1-AB22-1679DE7950CA wds:Q37711688-45195838-50BC-4CC5-B2F9-1551980BEEEF wds:Q37711688-4604AD94-A3FC-408E-9DEA-9B7A1FC35952 wds:Q37711688-47DCF6C6-4C46-4D10-9ED5-692C5312E4E5 wds:Q37711688-48FFC572-9657-47D2-9391-97034EAC07B6 wds:Q37711688-503A090D-F258-4AAF-B2AD-13B636477E92 wds:Q37711688-52CB3FCF-E251-4540-BB5A-CFBAB83C7F64 wds:Q37711688-52DE37B3-C594-48E6-A82C-0285A4B020DE wds:Q37711688-60ACC933-190A-4791-93E5-16A25466366E wds:Q37711688-70FCCC6A-91C4-46C4-8B8E-54EA91BFB025 wds:Q37711688-762FBE3C-AC3E-49D4-9A42-AA01EF725340 wds:Q37711688-77B181BA-214A-41F9-A976-7EE790FAD9F6 wds:Q37711688-7860DE06-F9CD-42E7-ADDC-3CD16483D5BA wds:Q37711688-79CE37A3-E93E-4BF2-B671-ED1DD9EF0B0F wds:Q37711688-7E9D66B4-059B-4C7C-A937-6BEA91E7BD67 wds:Q37711688-7FE34C29-E455-4D31-8CBC-28E335912A69 wds:Q37711688-85E0E24E-AEA7-4350-A206-73603A12BC16 wds:Q37711688-9D29A3F7-BEBA-4FF6-B179-03643CBF715D wds:Q37711688-AC8D1FBB-296F-4CD4-8B52-732BEE6E83B8 wds:Q37711688-B1FCF263-FB5E-45E6-90BA-FEE6201B7954 wds:Q37711688-C713E805-ACA8-43C8-8092-137423D0C219 wds:Q37711688-CF9ABF39-523F-4721-9988-02306D4A9C96 wds:Q37711688-D45913D0-60C6-405B-8E4C-07C230F32DBD wds:Q37711688-E44FD48C-0350-4EC1-93C3-20F30C94117D
cites work	Reduced PTEN expression is associated with poor outcome and angiogenesis in invasive ductal carcinoma of the breast Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer Trastuzumab containing regimens for early breast cancer Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas PIK3CA mutations in breast cancer are associated with poor outcome American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies Reduced expression of PTEN correlates with breast cancer progression PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
author name string	wds:Q37711688-1703C837-84E4-4DFB-AE1F-A494BA0AD5FA wds:Q37711688-18011DCD-29B9-464C-B074-D7096AA9EFF4 wds:Q37711688-3299A221-7310-4909-A4D2-93599BF96FB2 wds:Q37711688-3C6B027C-7D15-494D-8224-A8B1490C7B40 wds:Q37711688-56AEBADE-83C4-46C3-BAC1-688751D90E31 wds:Q37711688-6A8B2DBC-1E56-4490-98C3-56F90CC10CC2 wds:Q37711688-F747A4A2-66FF-4CB3-A813-4CAF21B082BD
author name string	E Büyükünal F Demirelli H Turna T Öztürk S Serdengecti D Tural S İlvan
rdfs:label	Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies (en) Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies (ast) Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. (nl)
skos:prefLabel	Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies (en) Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies (ast) Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. (nl)
name	Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies (en)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software